Amgen, Cytokinetics Announce Disappointing Phase 2 Data For Heart Failure ... Medical Daily (Amgen, Creative Commons) Co-developers Amgen and Cytokinetics announced disappointing results for omecamtiv mecarbil in a Phase 2 trial of the drug in patients with acute and chronic heart failure. Phase 2 testing of an intravenous formulation of ... UPDATED: PhII flop clouds future of Amgen, Cytokinetics heart failure drug Cytokinetics skids on heart failure drug data ATOMIC-AHF: Cautious optimism for potential inotrope replacement in acute HF |
